(Q34380025)

1 August 2017

Development of Vi conjugate - a new generation of typhoid vaccine (English)

1 reference

1 August 2017

1 reference

1 reference

Shousun Chen Szu

1

1 reference

1 August 2017

1 November 2013

1 reference

Expert Review of Vaccines

1 August 2017

1 reference

1 August 2017

12

1 reference

1 August 2017

1273-1286

1 reference

1 August 2017

11

1 reference

A study of typhoid fever in five Asian countries: disease burden and implications for controls

1 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Multidrug resistant Salmonella typhi in asymptomatic typhoid carriers among food handlers in Namakkal district, Tamil Nadu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Population impact of Vi capsular polysaccharide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Prospects for prevention of Salmonella infection in children through vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Serology of typhoid fever in an area of endemicity and its relevance to diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Sensitivity and specificity of typhoid fever rapid antibody tests for laboratory diagnosis at two sub-Saharan African sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Bacteremic typhoid fever in children in an urban slum, Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Typhoid fever in children aged less than 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Typhoid fever in Bangladesh: implications for vaccination policy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Vaccination and herd immunity: what more do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

A bivalent vaccine to protect against Streptococcus pneumoniae and Salmonella typhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Detection of O-acetylated Vi polysaccharide of Salmonella enterica subspecies typhi by enzyme immunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Effect of maternal antibodies on the infant immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM(197) glycoconjugate vaccine against Salmonella Typhi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

A human IgG anti-Vi reference for Salmonella typhi with weight-based antibody units assigned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Coalition against Typhoid (CaT): a new, global initiative to advance typhoid vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5-7 September 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

An optimization model for reducing typhoid cases in developing countries without increasing public spending

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Global trends in typhoid and paratyphoid Fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

A scalable method for O-antigen purification applied to various Salmonella serovars.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.845529

10.1586/14760584.2013.845529

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

24156285